Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain.

ABSTRACT:

Introduction

Aztreonam-avibactam (ATM-AVI) is the first β-lactam/β-lactamase inhibitor antibiotic for treating serious infections caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamases (MBL)-Enterobacterales. The objective of this analysis was to analyze the efficiency of ATM-AVI versus colistin + meropenem (COL+MER) in adult patients with complicated intra-abdominal infections (cIAI) or hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) based on the REVISIT study.

Methods

A model combining a decision tree and a Markov model has been adapted to the Spanish National Healthcare System perspective, considering a lifetime horizon. Patients' characteristics, clinical (probabilities of resistance, cure, mortality, recurrence, nephro

SUBMITTER: Aguilar G 

PROVIDER: S-EPMC12783401 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature